<?xml version="1.0" encoding="UTF-8"?>
<p>In this context regular review of emerging safety data by independent data and safety monitoring committees needs to remain the highest priority, and emerging data should be appropriately shared with regulatory authorities.
 <xref rid="bib67" ref-type="bibr">
  <sup>67</sup>
 </xref> The notion of a single submission point for clinical trial authorization with defined timelines for approval would further support these efforts.
</p>
